PD L1 News and Research

RSS

POSTECH researchers discover mechanism behind intestinal epithelial lymphocyte differentiation

The intestine harbors the largest number of immune cells in our body. Since the intestine is constantly exposed to various antigens like bacteria and food, appropriate induction of gut immune cells plays a pivotal role in gut homeostasis.

4 Feb 2021

Tiny molecular motions are of key significance in modern anti-cancer drugs

Modern immunotherapeutic anti-cancer drugs support a natural mechanism of the immune system to inhibit the growth of cancer cells.

3 Feb 2021

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

Researchers at Chicago University have developed an innovative new anti-SARS-CoV-2 therapy called “Nanotraps” – a family of nano-enabled virus-trapping particles – which have shown positive results in vitro, in vivo, and in human ex vivo trials.

3 Feb 2021

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

Substances in tick saliva activate immune response-suppressing proteins in cattle

A tick saliva study reveals immune responses that could lead to better protection for cattle.

28 Jan 2021

Potentially promising therapeutic combination for renal cell carcinoma uncovered

Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide.

20 Jan 2021

Study: Anal intraepithelial neoplasia is a precursor lesion for anal squamous cell carcinomas

Oncotarget recently published "PD-1/PD-L1 expression in anal squamous intraepithelial lesions" which reported that the presence and distribution of CD8 lymphocytes and the presence of PD-1 lymphocytes and PD-L1 epithelial cells were assessed.

12 Jan 2021

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer.

7 Jan 2021

Arthritis drug may be effective in treating immunotherapy-related heart complication

A drug typically prescribed for rheumatoid arthritis may also be effective in treating a rare but potentially deadly heart complication some cancer patients experience after taking immunotherapies, according to a study published in Cancer Discovery and co-led by investigators at Vanderbilt University Medical Center.

21 Dec 2020

Multisystem immune-related adverse events linked with improved survival from immunotherapy in NSCLC

The results of a large, retrospective study of patients who received a form of immunotherapy for non-small cell lung cancer (NSCLC) revealed that patients may get more than one immune-related side effect, and identified a correlation between these multisystem immune-related adverse events (irAEs) and improved patient survival.

14 Dec 2020

Combination therapy places no greater burden on early-stage breast cancer patients

Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows.

10 Dec 2020

Cancer-killing virus developed at City of Hope activates the immune system against colon cancer

City of Hope scientists have developed a cancer-killing virus by combining the oncolytic virus CF33 with an immune checkpoint inhibitor.

1 Dec 2020

Combination therapy found to be effective against treatment-resistant hepatocellular carcinoma

A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified by researchers at Massachusetts General Hospital.

30 Nov 2020

Dexamethasone use could reduce immune checkpoint inhibitor efficacy in glioblastoma patients

Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival.

25 Nov 2020

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

A study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute described a potential therapeutic anticancer vaccine that frees suppressed cancer-killing immune cells, enabling them to attack and destroy a tumor.

23 Nov 2020

Immunotherapies effective against lung cancer, melanoma may also work against rare skin tumor

Cutaneous angiosarcoma is a rare, highly aggressive skin tumor found primarily on the scalps of older White people, but based on new research from the University of North Carolina School of Medicine and the Lineberger Comprehensive Cancer Center, immunotherapies effective against lung cancer and melanoma may also work against this cancer.

18 Nov 2020

New tool predicts which cancer patients will respond positively to immunotherapy

An international group led by Dr Banafshe Larijani, an Ikerbasque researcher seconded to the Biofisika Institute (UPV/EHU-University of the Basque Country, CSIC), has developed a new diagnostic method making it possible to accurately predict which cancer patients will respond positively to immunotherapy.

16 Nov 2020

A promising vaccine for treating poorly immunogenic tumors

Patients with cancer have multiple treatment options available to them today, but each has its drawbacks. Chemotherapy kills rapidly dividing cancer cells, but it also damages healthy cells in the body and often does not effectively prevent tumor metastasis or disease recurrence.

11 Nov 2020

Novel molecules show potential for future cancer therapies

Cancers sometimes escape our immune defenses because of the over-activity of molecular signaling systems, called checkpoint processes. Now we may be able to fight back using a new range of molecules, researchers in China report in the European Journal of Medicinal Chemistry.

3 Nov 2020

Research details new strategy for overcoming treatment resistance by zeroing in on dendritic cells

Many of the most aggressive and hard-to-treat cancers are highly effective at blocking T cells, known as the foot soldiers of the immune system, from reaching and responding to tumors.

27 Oct 2020